


Y is -O-.


3. The compound of Claim 1 wherein

Y is -N- or -N-.




4. The compound of 1 wherein R^a is hydrogen, R^b is methyl, and R^c is hydrogen.


5. The compound of Claim 1 wherein




6. The compound of Claim 1 wherein R³



9. The compound of Claim 1 wherein




10. The compound of Claim 9 wherein m of



m is 3 or 4.

11. The compound of Claim 1 wherein R³ is -(CH₂)_n-C₁-C₆ alkyl.

12. The compound of Claim 1 wherein



14. The compounds:

[S-(R*,R*)]-[1-({2-(4-Benzyloxy-phenyl)-1-[(1-phenyl-cyclopropyl-methyl)-carbamoyl]-ethyl}-methyl-carbamoyl)-2-(3H-imidazol-4-yl)-ethyl]-carbamic acid benzyl ester; ← c/m 12

[S-(R*,R*)]-[1-[(2-(4-Benzyloxy-phenyl)-1-{[1-(2-fluoro-phenyl)-cyclopropylmethyl]-carbamoyl}ethyl)-methyl-carbamoyl]-2-(3H-imidazol-4-yl)-ethyl]-carbamic acid benzyl ester; and

[S-(R*,R*)]-[1-({2-(4-Benzyloxy-phenyl)-1-[(1-phenyl-cyclobutylmethyl)-carbamoyl]-ethyl}-methyl-carbamoyl)-2-(3H-imidazol-4-yl)-ethyl]-carbamic acid benzyl ester. ← c/m 11

19. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 and a pharmaceutically acceptable carrier.

REMARKS

Applicants will address each of the pending matters in this application in the order in which they appear in the Office Action of October 1, 2002. For the matters raised in the Office Action of January 2, 2002, Applicants maintain the arguments in their Response dated March 25, 2002.

Correction of Marked-Up Claims

Applicants enclose a corrected marked-up copy of the claims directed for amendment in Applicants' Response dated April 3, 2002. An automatic numbering computer program listed the claims in Applicants prior response numerically, rather than as originally typed. Applicants apologize for this oversight and thank the Examiner for bringing it to their attention.